Immatics (NASDAQ:IMTX – Free Report) – Cantor Fitzgerald issued their FY2025 EPS estimates for Immatics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.34) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.79) per share.
Other equities analysts also recently issued research reports about the company. Piper Sandler assumed coverage on Immatics in a report on Monday, October 7th. They issued an “overweight” rating and a $19.00 price objective for the company. Bank of America lowered their price target on shares of Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group upgraded shares of Immatics to a “strong-buy” rating in a report on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $16.67.
Immatics Stock Up 2.2 %
NASDAQ:IMTX opened at $5.57 on Wednesday. The firm’s fifty day simple moving average is $7.16 and its 200 day simple moving average is $9.70. The stock has a market cap of $664.84 million, a P/E ratio of -8.44 and a beta of 0.77. Immatics has a twelve month low of $5.27 and a twelve month high of $13.77.
Institutional Investors Weigh In On Immatics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in Immatics in the second quarter worth about $99,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in Immatics during the third quarter valued at approximately $114,000. Forefront Analytics LLC purchased a new stake in Immatics during the second quarter valued at approximately $139,000. Algert Global LLC bought a new position in Immatics in the second quarter worth approximately $242,000. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Immatics by 25.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 25,000 shares of the company’s stock worth $285,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
See Also
- Five stocks we like better than Immatics
- How to Calculate Options Profits
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Stock Dividend Cuts Happen Are You Ready?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.